BridgeBio Pharma, Inc. (BBIO) RWE: Acoramidis Cuts Clinical Worsening Risk 34% vs Tafamidis

BridgeBio reported peer-reviewed real-world data showing acoramidis was associated with a 34% lower risk of a composite of clinical worsening events vs tafamidis in ATTR-CM (p=0.046), with a 43% lower risk of diuretic intensification (p=0.021). Separation emerged within weeks.Material DetailsContex…